PL297849A1 - Vaccine against and method of treating the patients infectedwith hiv virus - Google Patents

Vaccine against and method of treating the patients infectedwith hiv virus

Info

Publication number
PL297849A1
PL297849A1 PL29784992A PL29784992A PL297849A1 PL 297849 A1 PL297849 A1 PL 297849A1 PL 29784992 A PL29784992 A PL 29784992A PL 29784992 A PL29784992 A PL 29784992A PL 297849 A1 PL297849 A1 PL 297849A1
Authority
PL
Poland
Prior art keywords
infectedwith
patients
treating
vaccine against
hiv virus
Prior art date
Application number
PL29784992A
Inventor
Gale E Smith
Franklin Volvovitz
Original Assignee
Microgenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microgenesys Inc filed Critical Microgenesys Inc
Publication of PL297849A1 publication Critical patent/PL297849A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL29784992A 1991-06-11 1992-06-10 Vaccine against and method of treating the patients infectedwith hiv virus PL297849A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71415291A 1991-06-11 1991-06-11
PCT/US1992/004980 WO1992022654A1 (en) 1991-06-11 1992-06-10 Vaccine and treatment method of human immunodeficiency virus infection

Publications (1)

Publication Number Publication Date
PL297849A1 true PL297849A1 (en) 1994-01-24

Family

ID=24868938

Family Applications (1)

Application Number Title Priority Date Filing Date
PL29784992A PL297849A1 (en) 1991-06-11 1992-06-10 Vaccine against and method of treating the patients infectedwith hiv virus

Country Status (18)

Country Link
EP (1) EP0542998A1 (en)
JP (1) JPH06501851A (en)
CN (1) CN1068266A (en)
AU (2) AU2193192A (en)
BG (1) BG97519A (en)
CA (1) CA2087732A1 (en)
EE (1) EE9400183A (en)
FI (1) FI930577L (en)
HU (1) HUT68355A (en)
IE (1) IE921875A1 (en)
IL (1) IL102092A (en)
LT (1) LT3365B (en)
MX (1) MX9202781A (en)
PL (1) PL297849A1 (en)
PT (1) PT100584A (en)
SK (1) SK18993A3 (en)
WO (1) WO1992022654A1 (en)
ZA (1) ZA924150B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40786E1 (en) * 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
AU1377395A (en) * 1993-12-23 1995-07-10 University Technologies International Inc. Methods of expressing proteins in insect cells and methods of killing insects
CN1192688A (en) 1995-06-07 1998-09-09 特莱默里斯公司 Treatment of HIV and other viral infections using combinatory therapy
US6395541B1 (en) 1996-05-23 2002-05-28 The Rockefeller University Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US6077662A (en) * 1996-11-27 2000-06-20 Emory University Virus-like particles, methods and immunogenic compositions
US6214540B1 (en) 1997-03-26 2001-04-10 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US6548631B1 (en) 1997-09-16 2003-04-15 BIOMéRIEUX, INC. Macrophage derived chemokine (MDC) as an anti-viral agent for the treatment and prevention of lentivirus infection
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
US6623741B1 (en) 2000-02-29 2003-09-23 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
AUPS065002A0 (en) 2002-02-20 2002-03-14 Immunaid Pty Ltd Strategy for retroviral immunotherapy
US7901690B2 (en) 2002-12-03 2011-03-08 University Of Massachusetts Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
BRPI0415533A (en) 2003-10-24 2006-12-26 Immunaid Pty Ltd therapy method
GT200800303A (en) 2007-12-24 2009-09-18 ANTI-RETROVIRAL COMBINATION
DK2435825T3 (en) 2009-05-27 2015-10-19 Biotempus Ltd Modes for medical care
EP2746394A4 (en) 2011-08-19 2015-07-15 Ostrich Pharma Kk ANTIBODY AND COMPOSITION CONTAINING THE SAME
CN102961760B (en) * 2011-09-01 2017-07-18 常州文松生物技术有限公司 Overlapping peptide used as reagent for preparing skin test and detecting specific cellular immunity and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1

Also Published As

Publication number Publication date
CA2087732A1 (en) 1992-12-12
PT100584A (en) 1993-07-30
MX9202781A (en) 1993-04-01
IL102092A (en) 1996-11-14
HUT68355A (en) 1995-06-28
BG97519A (en) 1994-03-24
IE921875A1 (en) 1992-12-16
FI930577A0 (en) 1993-02-10
EP0542998A1 (en) 1993-05-26
LT3365B (en) 1995-07-25
JPH06501851A (en) 1994-03-03
ZA924150B (en) 1993-02-24
IL102092A0 (en) 1993-01-14
AU2193192A (en) 1993-01-12
CN1068266A (en) 1993-01-27
SK18993A3 (en) 1993-10-06
WO1992022654A1 (en) 1992-12-23
AU4028895A (en) 1996-02-22
HU9300686D0 (en) 1993-06-28
FI930577A7 (en) 1993-03-24
LTIP335A (en) 1995-01-31
EE9400183A (en) 1995-12-15
FI930577L (en) 1993-03-24

Similar Documents

Publication Publication Date Title
ZA896864B (en) Method and composition for the treatment and prevention of viral infections
IL102092A0 (en) Vaccine and treatment method for human immunodeficiency virus
HU9602310D0 (en) Urease-based vaccine and treatment for helicobacter infection
LTIP863A (en) Aminobenzodiazepines, process for preparing thereof and application for the treatment and prevention of viral diseases
HU9302642D0 (en) Gp 160-derivatives and vaccine containing them or gp-160 itself
HU9202095D0 (en) Therapy and vaccine against aids
SG72610A1 (en) Therapeutic agent from my cobacterium vaccae and its use against hiv infection
ZA913949B (en) Diagnosis and treatment of viral hepatitis
EP0608212A4 (en) Method of treating viral infection.
EP0382551A3 (en) Prevention and treatment of herpes virus infections
EP0453497A4 (en) Treatment methods and vaccines
HU901571D0 (en) Vaccine and diagnostics against the virus of pig-cholera
HU9302183D0 (en) Medical preparatives for preventing and treating osteoporises after menopausa
IL102815A0 (en) Pharmaceutical compositions and method for the treatment of infection caused by the human immunodeficiency virus
EP0452360A4 (en) Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections
HU913022D0 (en) Fibroplast increasing factor for treating and preventing virus caused diseases
BG98272A (en) Preparation and method for the treatment of virus hepatitis
CS181491A3 (en) Vaccine for the prevention, prophylaxis and therapy of infectious diseasesof bones
PH27412A (en) Method of treatment of human immunodeficiency virus
EP0483086A3 (en) Process for the preparation of drugs for the treatment of hepatitis b, and drugs so obtained
GB9106540D0 (en) Aids therapy and vaccine
GB9020999D0 (en) Aids therapy and vaccine
GB9022330D0 (en) Aids therapy and vaccine
LTIP472A (en) Composition for the treatment of infection and disease caused by hepatit b virus
GB9013938D0 (en) Vaccine and treatment for the prevention of type i or juvenile diabetes